FY2020 · ended Dec 31, 2020 · Revenue $0 · Filed Mar 28, 2022
GT Biopharma, Inc. (GTBP) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$0
Net income (TTM)
$-46.28M
-97.1% vs year-ago TTM
Operating cash flow (TTM)
$-14.43M
-38.4% vs year-ago TTM
Free cash flow
$-3.66M
+65.8% vs prior year
EPS
$-6.68
+3.7% vs prior year
Dividend per share
None
Shares outstanding
31.55M
+1312.2% vs prior year
Net cash
$-44.03M
FY 2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GTBP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 109657
- Former names
- GT Biopharma, Inc. (until Oct 20, 2026); OXIS INTERNATIONAL INC (until Jul 25, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$12.4M | -$14.4M | -$13.6M | -$21.3M | -$57.5M |
| Net income | -$28.4M | -$13.2M | -$7.6M | -$20.9M | -$58.0M |
| Diluted EPS | -$6.68 | -$6.94 | -$5.64 | — | — |
| Operating cash flow | -$12.9M | -$12.9M | -$8.9M | -$15.2M | -$15.6M |
| Total assets | $8.1M | $4.2M | $14.1M | $16.7M | — |
| Total liabilities | — | — | $6.6M | $5.0M | — |
| Stockholders' equity | $5.8M | -$1.7M | $7.5M | $11.7M | $21.9M |
| Cash and investments | $6.8M | $4.0M | $14.0M | $16.5M | $23.0M |
| Total debt | — | — | $58.0M | $174,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 25, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Sep 21, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Sep 15, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Sep 3, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 883 GT Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.